Scientists try to 'reprogram' resistant cancer cells to accept chemo
NCT ID NCT04664829
Summary
This small, early-stage study tested whether a drug called bexarotene could make chemotherapy work better for people with a hard-to-treat, resistant form of metastatic breast cancer. Researchers enrolled 12 patients whose cancer had stopped responding to standard taxane drugs. The idea was that bexarotene might change the state of the cancer cells, making them more vulnerable to a follow-up chemotherapy treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Cancer Center Singapore
Singapore, 168583, Singapore
Conditions
Explore the condition pages connected to this study.